OpenOnco · Treatment Plan

Treatment plan — Acute Promyelocytic Leukemia

PLAN-VAR-APL-RELAPSED-V1 · v1 · 2026-05-13

Patient

VAR-APL-RELAPSED · Algorithm: ALGO-APL-2L

DiagnosisAcute Promyelocytic Leukemia

MOH / ICD-10C92.4

ICD-O-39866/3; C42.1

Clinical significance of mutations (ESCAT)

Tumor-board context — the engine does not use these tiers to rank tracks

Biomarker	Variant	ESCAT	Evidence	Clinical significance	Drugs	Sources
No clinically actionable variants matched in this profile.

Primary current-line option

Aggressive plan

★ DEFAULT

Indication

IND-APL-SALVAGE-ATRA-ATO

Regimen

ATRA + ATO salvage for R/R APL post front-line

Drugs + NSZU

All-trans retinoic acid (DRUG-ATRA) 45 mg/m²/day PO in 2 divided doses, continuous through induction · Days 1-60 induction (until molecular CR); thereafter maintenance per protocol · PO ✓ NSZU covered
Arsenic trioxide (DRUG-ATO) 0.15 mg/kg/day IV (2-hour infusion) daily until molecular CR (typically 4-8 weeks) · Daily during induction; consolidation cycles 5 days/week × 4 weeks q8wk × 4 cycles · IV ✓ NSZU covered

Supportive care

SUP-TLS-PROPHYLAXIS, SUP-HBV-PROPHYLAXIS

Reason

Primary current-line option selected by ALGO-APL-2L at step 4.

Pre-treatment investigations

Investigations before treatment start · critical / standard / desired · merged across tracks

ID	Name	Priority	Category	Where to order	Needed for
TEST-BM-ASPIRATE	Bone Marrow Aspirate	Critical	histology	—	all tracks
TEST-BM-TREPHINE	Bone Marrow Trephine	Critical	histology	—	all tracks
TEST-CBC	Complete Blood Count with Differential	Critical	lab	—	all tracks
TEST-CMP	Comprehensive Metabolic Panel	Critical	lab	—	all tracks
TEST-COAG-PANEL	Coagulation Panel	Critical	lab	—	all tracks
TEST-FISH-PANEL	FISH (Fluorescence In Situ Hybridization)	Critical	genomic	CSD Lab ✓ (code TBC)	all tracks
TEST-FLOW-CYTOMETRY	Flow Cytometry	Critical	histology	CSD Lab ✓ (code TBC)	all tracks
TEST-HBV-SEROLOGY	Hepatitis B Serology Panel (HBsAg, anti-HBc total, anti-HBs)	Critical	lab	—	all tracks
TEST-HCV-ANTIBODY	HCV Antibody	Critical	lab	—	all tracks
TEST-HIV-SEROLOGY	HIV Antibody/Antigen	Critical	lab	—	all tracks
TEST-KARYOTYPE	Karyotype	Critical	genomic	CSD Lab ✓ (code TBC)	all tracks
TEST-LDH	Lactate Dehydrogenase	Critical	lab	—	all tracks
TEST-LFT	Liver Function Tests (ALT, AST, bilirubin, ALP, GGT, albumin)	Critical	lab	—	all tracks
TEST-NGS-MYELOID-PANEL	Myeloid NGS Panel	Critical	genomic	CSD Lab ✓ (code TBC)	all tracks
TEST-PERIPHERAL-SMEAR	Peripheral Blood Smear	Critical	lab	CSD Lab ✓ (code TBC)	all tracks
TEST-PREGNANCY	Beta-HCG	Critical	lab	—	all tracks
TEST-ECHO	Echocardiography	Standard	imaging	—	all tracks
TEST-D-DIMER	D-Dimer	Desired	lab	—	all tracks

Red flags — PRO / CONTRA aggressive

PRO-AGGRESSIVE

Triggers that push toward the aggressive track

APL with active disseminated intravascular coagulation (DIC): fibrinogen <150 mg/dL, prolonged PT/PTT, elevated D-dimer, thrombocytopenia + bleeding manifestations. Initiate ATRA AT CLINICAL SUSPICION before cytogenetic confirmation.RF-APL-EMERGENCY-DIC
APL patient elderly (age ≥70) or frail (ECOG ≥2 with comorbidities) — chemo-free ATRA + ATO is preferred even for high-risk if anthracycline tolerance is concerning; toxicity profile of AIDA poorly tolerated >70RF-APL-FRAILTY-AGE
APL with cardiac comorbidity making ATO problematic: baseline QTc >500 ms, uncorrected hypokalemia (<3.5) or hypomagnesemia (<1.8), pre-existing arrhythmia OR severe hepatic dysfunction (bilirubin >3× ULN, transaminases >5× ULN)RF-APL-ORGAN-DYSFUNCTION

CONTRA-AGGRESSIVE

Hard contraindications to escalation

What NOT to do

Explicit prohibitive rules, each grounded in a regimen / supportive care / contraindication entity

Aggressive plan (IND-APL-SALVAGE-ATRA-ATO)

Do NOT start without verified PML-RARA molecular relapse — APL relapse is often molecular only (PCR+ MRD); confirm before salvage.
Do NOT skip DS prophylaxis with steroids on rising WBC — DS-leading-cause-of-death in APL induction.
Do NOT start ATO without daily ECG + electrolyte correction (K+ >4.0, Mg2+ >1.8) — torsades risk.
Do NOT ignore DIC management at relapse onset — fibrinogen >150, plt >30-50K.
Do NOT forget the autoSCT-pathway for fit molecularly-CR responders — substantially extends OS.
Do NOT consider alloHCT as 1st-choice salvage for CR-responders — autoSCT has lower TRM with comparable outcomes.
Do NOT continue ATRA + ATO maintenance solely without consolidation autoSCT for fit responders.

Timeline

Treatment timeline — derived from regimen + monitoring schedule

Aggressive plan

Induction · ATRA + ATO salvage for R/R APL post front-line

28-day cycles × Induction until molecular CR (typically 4-8 weeks) + 4 consolidation cycles + autoSCT consolidation for fit molecularly-CR responders

MDT brief

Discussion questions (1, 0 blocking)

OQ-LDH-CURRENT
What is the current LDH? Marker of tumor burden and transformation.
LDH is part of the prognostic indices of indolent lymphomas.
→ hematologist

MDT talk tree (2 steps)

#	Owner	Topic	Action
1	hematologist	Staging / disease burden	What is the current LDH? Marker of tumor burden and transformation.
2	clinical_pharmacist	Specialist review	Chemoimmunotherapy regimen — drug-drug interactions, dose adjustments, premedication.

Skills (recommended) — for consideration (1)

Clinical pharmacist recommended
Chemoimmunotherapy regimen — drug-drug interactions, dose adjustments, premedication.

Data quality

Usable with caveats. No critical default-track gap was found, but the MDT should review the listed caveats before final sign-off.

Biomarker coverage: 0/0 known (100%), 0 missing, 0 default-track gaps
Unevaluated RedFlags: RF-APL-EMERGENCY-DIC, RF-APL-FRAILTY-AGE, RF-APL-HIGH-RISK-BIOLOGY, RF-APL-INFECTION-SCREENING, RF-APL-ORGAN-DYSFUNCTION, RF-APL-TRANSFORMATION-PROGRESSION, RF-SANZ-HIGH-RISK, RF-SANZ-INTERMEDIATE, RF-SANZ-LOW-RISK

Technical MDT skill metadata (1/16 activated in this plan)

All registered virtual specialists. ✓ — activated for this case; ○ — not activated (available for other clinical scenarios).

Specialist	skill_id	Version	Last reviewed	Domain
Cellular therapy specialist (CAR-T)	`cellular_therapy_specialist`	v0.1.0	2026-04-25	cellular_therapy
Clinical pharmacist	`clinical_pharmacist`	v0.1.0	2026-04-25	clinical_pharmacy
Hematologist / oncohematologist	`hematologist`	v0.1.0	2026-04-25	hematology_oncology
Hematopathologist (lymphoma / leukemia / myeloma)	`hematopathologist`	v0.1.0	2026-04-25	hematopathology
Infectious disease / hepatology	`infectious_disease_hepatology`	v0.1.0	2026-04-25	infectious_diseases
Medical oncologist (solid-tumor chemotherapist)	`medical_oncologist`	v0.1.0	2026-04-25	solid_oncology
Molecular geneticist / molecular oncologist	`molecular_geneticist`	v0.1.0	2026-04-25	molecular_oncology
Palliative care	`palliative_care`	v0.1.0	2026-04-25	palliative_care
Pathologist (general)	`pathologist`	v0.1.0	2026-04-25	pathology
Primary care / family physician	`primary_care`	v0.1.0	2026-04-25	primary_care
Psycho-oncologist	`psychologist`	v0.1.0	2026-04-25	psychosocial
Radiation oncologist	`radiation_oncologist`	v0.1.0	2026-04-25	radiation_oncology
Radiologist	`radiologist`	v0.1.0	2026-04-25	diagnostic_imaging
Social worker / case manager	`social_worker_case_manager`	v0.1.0	2026-04-25	psychosocial
Surgical oncologist	`surgical_oncologist`	v0.1.0	2026-04-25	surgical_oncology
Transplant specialist (BMT)	`transplant_specialist`	v0.1.0	2026-04-25	cellular_therapy

Sources cited

SRC-APL-RELAPSE-LENGFELDER-2017: Outcomes of patients with relapsed acute promyelocytic leukemia treated with all-trans retinoic acid + arsenic trioxide salvage regimens (2017)
SRC-ELN-APL-2019: Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet (2019)
SRC-NCCN-AML-2025: NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia (v.X.2025)

Experimental options (clinical trials)

Third plan track — open-enrollment trials from ClinicalTrials.gov. Render-time metadata; engine selection is not affected by this block (CHARTER §8.3). Last synced: 2026-05-13.

NCT	Title	Phase	Status	Sponsor	UA	Signals
NCT02390635	PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia	PHASE1	RECRUITING	M.D. Anderson Cancer Center	—	Phase 1 only Single country
NCT04897490	RWE of 1st Line Treatment With ATO/ATRA for Adult APL	N/A	RECRUITING	Grupo Argentino de Tratamiento de la Leucemia Aguda	—	Single country
NCT05832320	Optimum Induction Therapy of Low-risk APL	NA	RECRUITING	Peking University People's Hospital	—	Single country
NCT05881265	Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia	PHASE2	RECRUITING	Shanghai Jiao Tong University School of Medicine	—	Small N (<50) Single country
NCT06450145	Evaluate the Efficacy and Safety of Interferon-α Combined With ATO in the Treatment of Arsenic-resistant APL	NA	RECRUITING	Zhejiang Provincial People's Hospital	—	Small N (<50) Surrogate endpoint only Single country
NCT02390752	Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...	PHASE1	RECRUITING	National Cancer Institute (NCI)	—	Phase 1 only Single country
NCT06982274	Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia	PHASE2	RECRUITING	Instituto do Cancer do Estado de São Paulo	—	Single country
NCT01409161	Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia	PHASE2	RECRUITING	M.D. Anderson Cancer Center	—	Single country
NCT07504458	Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia	PHASE3	RECRUITING	Quetzal Therapeutics	—	Single country
NCT04793919	Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia	PHASE2	RECRUITING	Associazione Italiana Ematologia Oncologia Pediatrica	—	—

Verify recruitment status directly with the trial site. ctgov data can lag behind current UA-site status.

Option availability in Ukraine

Per-track UA registration · NSZU · cost · access pathway. Render-time metadata; engine selection does not depend on these fields (CHARTER §8.3).

Option	UA registration	NSZU	Cost orientation	Access pathway
Aggressive plan ATRA + ATO salvage for R/R APL post front-line (REG-ATRA-ATO-APL-SALVAGE)	✓ registered	✓ covered	₴-? — verify pathway	NSZU formulary
Trial · NCT02390635 PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT04897490 RWE of 1st Line Treatment With ATO/ATRA for Adult APL No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT05832320 Optimum Induction Therapy of Low-risk APL No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT05881265 Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06450145 Evaluate the Efficacy and Safety of Interferon-α Combined With ATO in the Treatment of Arsenic-resistant APL No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT02390752 Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ... No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT06982274 Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT01409161 Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT07504458 Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor
Trial · NCT04793919 Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia No UA site listed — international referral required	— unknown	— unknown	self-pay: ₴0/course	Trial sponsor

Cost information is orientation. Verify with a specific pharmacy / foundation / trial site. Status updated: 2026-05-13.

plan_id: PLAN-VAR-APL-RELAPSED-V1 | version: 1 | generated: 2026-05-13T10:01:51.676248+00:00

Per FDA non-device CDS positioning (CHARTER §15): Outpatient oncology treatment planning to support tumor-board discussion. Not a medical device; not for autonomous clinical decision-making.

Per FDA non-device CDS positioning (CHARTER §15): Both treatment options below are presented for review. The engine's selection of a 'recommended' default does not constitute a clinical decision. Final treatment selection requires HCP judgment incorporating information not available to the system.

This document is an informational resource supporting tumor-board discussion (per CHARTER §11). It is not a system that makes clinical decisions. Every recommendation must be verified by the treating physician.